Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
With data showing superiority over glucocorticoids, Chemocentryx could have a new standard of care for vasculitis in avacopan.
Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.